The influence of antihypertensive treatment on arterial stiffness and selected matrix metalloproteinases plasma activity
The aim of the study was to compare the effects of 5 selected drugs on arterial stiffness and matrix metalloproteinases (MMPs) plasma activity in patients with essential arterial hypertension (HT).Material and methods: 95 pts. with HT stage 1 and 2, (N=19 in each treatment group) were treated for 6 months by: quinapril 20-40 mg/d (group-1), amlodipine 5-10mg/d (group-2), hydrochlorothiazide 12,5-25mg/d (group-3), losartan 50-100 mg/d (group 4), bisoprolol 5-10 mg/d (group-5). Before and then after 1,3 and 6 months of treatment office blood pressure (BP) was measured using Omron M5-I device. Carotid femoral pulse wave velocity (PWV) was measured using 3 devices Complior®, Sphygmocor® and ArteriographTM.. Plasma concentration of (MMPs): MMP1, MMP2, MMP3, MMP9 and MMPs tissue inhibitor (TIM...
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function
Biomarkers are being increasingly used in the study of cardiovascular disease because they provide readily quantifiable surrogate endpoints and allow accurate assessment of the effects of therapy on particular pathological processes. However, in order to be useful, biomarkers must be relevant, predictable, accurate, and reproducible. There is compelling evidence from large-scale clinical trials that inhibitors of the reninndash;angiotensin system [angiotensin-converting enzyme inhibitors and angiotensin type II receptor blockers (ARBs)] and calcium channel blockers (CCBs) may have beneficial effects beyond blood pressure control in the treatment of hypertension. Biomarkers are expected to provide further insight into these beneficial effects and allow for quantitative assessment. This rev...
